RNAC Q4 2020 Earnings — Cartesian Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

RNACCartesian Therapeutics, Inc.

$216M

Q4 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$12M+79.6% YoY

Gross Profit

$12M100.0% margin

Operating Income

-$8M-66.1% margin

Net Income

-$15M-129.2% margin

EPS (Diluted)

$-4.30

QoQ Revenue Growth

+157.2%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$165M

Total Liabilities

$183M

Stockholders' Equity

-$18M

Cash & Equivalents

$139M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$12M	$7M	+79.6%
Gross Profit	$12M	$7M	+79.6%
Operating Income	-$8M	-$13M	+37.2%
Net Income	-$15M	-$15M	-3.7%